Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib after Pazopanib in mRCC
NCT02122003Phase 2Terminated
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Sep 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in metastatic renal cell carcinoma (mRCC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Started Sep 2016; status: terminated.
02
Drugs
sorafenib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT02122003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02122003.